[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"facial-wrinkles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:facial-wrinkles":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100648572","evaluation-of-sofwave-sofware-guided-energy-delivery-for-lower-face-and-neck-rejuvenation-100648572",false,"NCT07723664","Evaluation of SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation","Inclusion Criteria:\n\n1. Healthy female and male subjects between the ages 40-55.\n2. Non-Smoker.\n3. Fitzpatrick skin type I-VI.\n4. Desire to lift facial lax skin, neck and\u002For submental and\u002For improve facial wrinkles appearance.\n5. Presence of mild to moderate laxity in the lower face and submental area.\n6. Able and willing to comply with all visits, treatments and evaluation schedules and requirements.\n7. Able to understand and provide written Informed Consent.\n8. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.\n9. Subject agrees not to undergo any other facial cosmetic treatment for a period of 3 months following last SofWave treatment.\n10. Stable weight over the last 12 weeks and throughout the duration of the study.\n11. Subjects agree to adhere to safe sun practices and daily use of broad-spectrum sunscreen SPF 30+.\n12. Male subjects with facial hair in the treatment area are willing to trim or shave as needed to allow consistent standardized photography.\n\n    \\-\n\nExclusion Criteria:\n\n1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and\u002For breast feeding.\n2. Presence of any active systemic or local infections.\n3. Open wounds or lesions within the intended to treat area.\n4. Tattoo or former tattoo at or near treatment area.\n5. Presence of active local skin disease that may alter wound healing.\n6. Uncontrolled diabetes mellitus.\n7. Skin cancer in the area to be treated. History of any other non-melanoma skin cancers in the past 5 years within the treatment area (head and neck).\n8. Severe solar elastosis.\n9. History of smoking in the past 10 years.\n10. History of chronic drug or alcohol abuse.\n11. Excessive subcutaneous fat on the cheeks.\n12. Significant scarring in the area to be treated or history of keloids.\n13. Severe or cystic facial acne, and\u002For Accutane use during the past 6 months.\n14. Pacemakers and electronic device implants in the treated area.\n15. Presence of a metal stent or implant in the facial area (dental implants and\u002For braces are not excluded).\n16. Inability to understand the protocol or to provide a signed informed consent.\n17. History of cosmetic treatments in the area to be treated including:\n\n    * Chemical peels, microneedling, dermabrasion, energy-based devices, or laser treatments in the past 6 months\n    * Injectable filler treatments in the past 6 months\n    * Injectable neuromodulator treatment in the past 4 months\n18. Cosmetic surgical procedures in the treatment area, including but not limited to facelift in the past 12 months.\n19. Taking anti-platelet or anti-coagulant within the past 2 weeks.\n20. Ongoing use of psychiatric medication; taking psychiatric drugs within the past 2 weeks.\n21. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.\n\n    \\-",true,"ALL","40 Years","55 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Non-randomized single-arm prospective clinical study.",[27,28,29],"Facial Wrinkles","Jawline Contour","Skin Laxity",[31,32,33,34,35,36],"lower face","upper neck","submental","facial wrinkles","jawline contour","skin laxity","NOT_YET_RECRUITING","2026-07-23",{"date":40,"type":41},"2026-07-27","ACTUAL",{"date":43,"type":21},"2026-07-20",{"date":45,"type":21},"2027-07-15",{"name":47,"class":48},"Sofwave Medical LTD","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100565186","phase-2-efficacy-and-safety-of-skincare-serum-and-cream-for-anti-aging-of-facial-skin-100565186","NCT06638905","Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin","A Prospective, Open Label Clinical Study Evaluating the Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin","Inclusion Criteria:\n\n* Men and women between the ages of 18 and 50 years old (inclusive).\n* Subjects must be able and willing to provide written informed consent and photography release.\n* At the baseline evaluation, all subjects must exhibit mild to moderate skin aging, as defined below (Appendix A):\n\n  1. Class I-II of Wrinkling on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale\n  2. Score 1-6 of Degree of Elastosis on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale\n  3. Mild to Moderate on Redness\u002FErythema Grading Scale\n  4. Mild to Moderate on Dryness\u002FScaling\u002FRoughness Grading Scale\n  5. Mild to Moderate on Luminosity Scale\n* Subject must be in good general health with no other skin disease, disease state or physical condition which would impair evaluation of the areas to be treated or which would increase the subject's health risk by study participation.\n* Subjects must have a willingness to minimize sun exposure, avoid direct sun exposure on the face, and avoid the use of tanning beds for the entire duration of the study. Must be willing to wear a hat and reapply sunscreen if sun exposure is unavoidable.\n* Subjects must be willing and able to understand and comply with the requirements of the study including prolonged sun exposure and apply the products as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n  1. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n  2. Acceptable methods of birth control are: oral contraceptives, contraceptive patches\u002Frings\u002Fimplants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and\u002For vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.\n\nExclusion Criteria:\n\n* Subjects who are pregnant, planning pregnancy during the course of the study, or breastfeeding.\n* Subjects with an active bacterial, fungal, or viral infection in the treatment area\n* Subjects with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n* Subjects receiving any topical products containing tretinoins or derivatives, alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the face within 14 days prior to or during the study period, other than the study products.\n* Subjects receiving a chemical peel, any systemic steroids, a non-ablative laser, ablative laser, microfocused ultrasound, light or radio frequency treatment, deep chemical peel, and\u002For has had a Dermabrasion on their face must have discontinued the drug\u002Ftreatment and\u002For had the procedure at least 6 months prior to entering the study.\n* Subjects who have had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to and not willing to refrain from use for the duration of the study period.\n* Subjects with recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds\u002Fbooths and\u002For sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry.\n* Subjects that has previously been treated with a systemic retinoid within the past 3 months (e.g., Accutane®, Roche Dermatologics).\n* Subjects with a history of keloids or hypertrophic scars.\n* Subjects with known allergies to any of the product ingredients.\n* Subjects with a tattoo and\u002For scar in the treatment area that in the investigators opinion would interfere with study assessments.\n* Subjects with history of or the presence of any skin condition\u002Fdisease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the investigator.\n* Inability to comply with all study protocol restrictions and visits.\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.\n* History of non-compliance with clinical research protocols.","18 Years","50 Years",{"count":60,"type":21},18,[62,63],"PHASE2","PHASE3","The primary objective of this study is to assess the efficacy and safety of combination therapy of BABOR® Ultimate ECM Repair Serum and the BABOR® Cure Cream for the improvement of anti-aging through the use of investigator assessments, subject questionnaires\u002Fassessments, photography, skin imaging, and reported adverse reactions.",[27,66],"Skin Aging",[68,69,70,71],"Wrinkles","Face Wrinkles","Cosmetic","Crow's Feet","2024-10-09",{"date":74,"type":41},"2024-10-15",{"date":76,"type":21},"2024-10-28",{"date":78,"type":21},"2025-05-05",{"name":80,"class":81},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER"]